Motolese M, Muiesan G, Colombi A
Eur J Clin Pharmacol. 1975;8(1):21-31. doi: 10.1007/BF00616411.
In a multicentre, double-blind, between-patient study the hypotensive effect of oxprenolol was investigated in 329 patients with mild to moderate hypertension. A factorial experimental design with three factors was chosen: oxprenolol--none or daily doses of 20, 40, 60 and 80 mg; dihydralazine and hydrochlorothiazide, respectively, none or 30 mg daily. Each treatment was given for 4 weeks after an adequate period of withdrawal from any other possible hypotensive therapy and one week of placebo wash-out. Irresponsive of the association with dihydralazine and/or hydrochlorothiazide, oxprenolol had a hypotensive effect linearly related to dose for standing systolic (P less than 0.05) and diastolic (P less than 0.01) pressure, and for lying diastolic (P less than 0.05) pressure. The additional of dihydralazine enhanced the time-course of the hypotensive effect of oxprenolol, particularly the 80 mg dose level. In general, the combination of oxprenolol with dihydralazine and hydrochlorothiazide caused larger reductions in blood pressure, particularly with oxprenolol 80 mg. In the latter group, the eventual falls in blood pressure were 30.5 and 14.4 mmHg for lying systolic and diastolic, respectively; and 32.1 and 20.0 mmHg for the standing systolic and diastolic pressures. The drug was well tolerated; major side effects (heart failure and bronchospasm) occurred in three patients.
在一项多中心、双盲、患者间对照研究中，对329例轻至中度高血压患者研究了氧烯洛尔的降压作用。采用了包含三个因素的析因实验设计：氧烯洛尔——无用药或每日剂量20、40、60和80毫克；分别为双肼屈嗪和氢氯噻嗪，无用药或每日30毫克。在充分停用任何其他可能的降压治疗并经过一周安慰剂洗脱期后，每种治疗给药4周。无论与双肼屈嗪和/或氢氯噻嗪联合使用情况如何，氧烯洛尔对站立位收缩压（P<0.05）和舒张压（P<0.01）以及卧位舒张压（P<0.05）均有与剂量呈线性相关的降压作用。添加双肼屈嗪可增强氧烯洛尔降压作用的时间进程，尤其是80毫克剂量水平。一般而言，氧烯洛尔与双肼屈嗪和氢氯噻嗪联合使用导致血压下降幅度更大，尤其是氧烯洛尔80毫克组。在后一组中，卧位收缩压和舒张压最终分别下降30.5和14.4毫米汞柱；站立位收缩压和舒张压分别下降32.1和20.0毫米汞柱。该药物耐受性良好；3例患者出现主要副作用（心力衰竭和支气管痉挛）。
